Source: FierceBiotech UCB Pharma has struck a $2.5 billion (€2.2 billion) deal to acquire Ra Pharmaceuticals. The takeover will give UCB control of a phase 3 rival to Alexion’s Soliris that some analysts have tipped to rack up blockbuster sales. Ra is focused on a once-daily, self-administered, subcutaneous C5 inhibitor called zilucoplan.…...